Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide.
The latest research on Viatris centers on a revised price target of US$22 per share and what that figure implies for investors following the story. Analysts are split, with more optimistic views pointing to execution on the product pipeline and cautious views questioning how fully the current stock price already reflects those expectations. As the article continues, you will see how this updated target fits into the evolving narrative around Viatris and how you can track the key signposts from here.
Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Viatris.
Barclays lifted its Viatris price target to US$22 from US$17 and kept an Overweight rating, which signals a more constructive view on where the stock could trade over time.
The analyst at Barclays highlighted what was described as strong Q1 results for Viatris, which supports confidence in the company's current execution.
Barclays pointed to an expected slate of product approvals this year for Viatris, which the firm believes will help set up the company's longer term growth profile.
The same research comment argued that as Viatris closes the revenue growth gap to peers, its valuation multiple could trend higher over time.
Even with the higher US$22 target from Barclays, the research highlights that part of the argument relies on Viatris narrowing a revenue growth gap to peers, which may take time and is not yet fully proven.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!
We've flagged 1 risk for Viatris. See which could impact your investment.
The fair value estimate for Viatris has moved from US$17.94 to US$18.50 per share.
The revenue growth assumption has shifted from 2.00% to 1.84%.
The profit margin expectation has changed from 4.50% to 4.92%.
The assumed future P/E multiple has adjusted from 36.72x to 34.43x.
The discount rate has moved from 7.11% to 7.24%.
Narratives connect Viatris' business story to analyst forecasts and a fair value estimate that update as new data comes in. They help you see how product news, guidance changes, and risks fit into one clear framework.
Head over to the Simply Wall St Community and follow the Narrative on Viatris to stay up to date on:
How expansion in emerging markets such as Greater China and emerging Asia, alongside late stage pipeline assets in chronic disease, pain, and ophthalmology, support broader revenue streams.
The shift toward higher margin complex generics, biosimilars, and branded products, combined with company wide cost and efficiency measures, that is intended to support higher net margins.
Key pressure points including reliance on mature generics, price and regulatory pressure in major markets, operational remediation at facilities like Indore and Nashik, and competition from lower cost manufacturers.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include VTRS.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]